Search

Your search keyword '"Gay, Francesca"' showing total 1,034 results
Start Over Author "Gay, Francesca" Search Limiters Academic (Peer-Reviewed) Journals
1,034 results on '"Gay, Francesca"'

1. An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma

Author

de Jong, Madelon M. E., Fokkema, Cathelijne, Papazian, Natalie, Czeti, Ágnes, Appelman, Marjolein K., Vermeulen, Michael, van Heusden, Teddie, Hoogenboezem, Remco M., van Beek, Gregory, Tahri, Sabrin, Sanders, Mathijs A., van de Woestijne, Pieter C., Gay, Francesca, Moreau, Philippe, Büttner-Herold, Maike, Bruns, Heiko, van Duin, Mark, Broijl, Annemiek, Sonneveld, Pieter, and Cupedo, Tom

Published
2024
Full Text
View/download PDF

2. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells

Author

D’Agostino, Mattia, Rota-Scalabrini, Delia, Belotti, Angelo, Bertamini, Luca, Arigoni, Maddalena, De Sabbata, Giovanni, Pietrantuono, Giuseppe, Pascarella, Anna, Tosi, Patrizia, Pisani, Francesco, Pescosta, Norbert, Ruggeri, Marina, Rogers, Jennifer, Olivero, Martina, Garzia, Mariagrazia, Galieni, Piero, Annibali, Ombretta, Monaco, Federico, Liberati, Anna Marina, Palmieri, Salvatore, Stefanoni, Paola, Zamagni, Elena, Bruno, Benedetto, Calogero, Raffaele Adolfo, Boccadoro, Mario, Musto, Pellegrino, and Gay, Francesca

Published
2024
Full Text
View/download PDF

3. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.

Author

Davies, Faith, Pawlyn, Charlotte, Usmani, Saad, San-Miguel, Jesus, Einsele, Hermann, Boyle, Eileen, Corre, Jill, Auclair, Daniel, Cho, Hearn, Lonial, Sagar, Sonneveld, Pieter, Stewart, A, Bergsagel, P, Kaiser, Martin, Weisel, Katja, Keats, Jonathan, Mikhael, Joseph, Morgan, Kathryn, Ghobrial, Irene, Orlowski, Robert, Landgren, C, Gay, Francesca, Caers, Joseph, Chng, Wee, Chari, Ajai, Walker, Brian, Kumar, Shaji, Costa, Luciano, Anderson, Kenneth, and Morgan, Gareth

Subjects
Humans, Multiple Myeloma, Prognosis
Abstract

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Published
2022

4. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

Author

Rodriguez-Otero, Paula, Usmani, Saad, Cohen, Adam D, van de Donk, Niels W C J, Leleu, Xavier, Gállego Pérez-Larraya, Jaime, Manier, Salomon, Nooka, Ajay K, Mateos, Maria Victoria, Einsele, Hermann, Minnema, Monique, Cavo, Michele, Derman, Benjamin A, Puig, Noemi, Gay, Francesca, Ho, P Joy, Chng, Wee-Joo, Kastritis, Efstathios, Gahrton, Gösta, Weisel, Katja, Nagarajan, Chandramouli, Schjesvold, Fredik, Mikhael, Joseph, Costa, Luciano, Raje, Noopur S, Zamagni, Elena, Hájek, Roman, Weinhold, Niels, Yong, Kwee, Ye, Jing Christine, Sidhana, Surbhi, Merlini, Giampaolo, Martin, Tom, Lin, Yi, Chari, Ajai, Popat, Rakesh, and Kaufman, Jonathan L

Published
2024
Full Text
View/download PDF

5. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

Author

Bandini, Cecilia, Mereu, Elisabetta, Paradzik, Tina, Labrador, Maria, Maccagno, Monica, Cumerlato, Michela, Oreglia, Federico, Prever, Lorenzo, Manicardi, Veronica, Taiana, Elisa, Ronchetti, Domenica, D’Agostino, Mattia, Gay, Francesca, Larocca, Alessandra, Besse, Lenka, Merlo, Giorgio Roberto, Hirsch, Emilio, Ciarrocchi, Alessia, Inghirami, Giorgio, Neri, Antonino, and Piva, Roberto

Published
2023
Full Text
View/download PDF

7. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Author

Terpos, Evangelos, Musto, Pellegrino, Engelhardt, Monika, Delforge, Michel, Cook, Gordon, Gay, Francesca, van de Donk, Niels W. C. J., Ntanasis-Stathopoulos, Ioannis, Vangsted, Annette Juul, Driessen, Christoph, Schjesvold, Fredrik, Cerchione, Claudio, Zweegman, Sonja, Hajek, Roman, Moreau, Philippe, Einsele, Hermann, San-Miguel, Jesus, Boccadoro, Mario, Dimopoulos, Meletios A., Sonneveld, Pieter, and Ludwig, Heinz

Published
2023
Full Text
View/download PDF

8. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Author

Holstein, Sarah A, Bahlis, Nizar, Bergsagel, P Leif, Bhutani, Manisha, Bolli, Niccolo, Brownstein, Carrie, Demolis, Pierre, Foureau, David, Gay, Francesca, Ghobrial, Irene M, Gormley, Nicole, Hillengass, Jens, Kaiser, Martin, Maus, Marcela V, Melenhorst, J Joseph, Merz, Maximilian, Dwyer, Michael O, Paiva, Bruno, Pasquini, Marcelo C, Shah, Nina, Wong, Sandy W, Usmani, Saad Z, and McCarthy, Philip L

Subjects
Transplantation, Rare Diseases, Cancer, Hematology, Good Health and Well Being, Humans, Bone Marrow, Diterpenes, High-Throughput Nucleotide Sequencing, Multiple Myeloma, Neoplasm, Residual, Minimal residual disease, Immune profiling, Multiple myeloma, Endpoint, CAR T-cell, Cellular therapy
Abstract

The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.

Published
2021

9. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

Author

van de Donk, Niels W C J, Minnema, Monique C, van der Holt, Bronno, Schjesvold, Fredrik, Wu, Ka Lung, Broijl, Annemiek, Roeloffzen, Wilfried W H, Gadisseur, Alain, Pietrantuono, Giuseppe, Pour, Ludek, van der Velden, Vincent H J, Lund, Thomas, Offidani, Massimo, Grasso, Mariella, Giaccone, Luisa, Razawy, Wida, Tacchetti, Paola, Mancuso, Katia, Silkjaer, Trine, Caers, Jo, Zweegman, Sonja, Hájek, Roman, Benjamin, Reuben, Vangsted, Annette Juul, Boccadoro, Mario, Gay, Francesca, Sonneveld, Pieter, and Musto, Pellegrino

Published
2023
Full Text
View/download PDF

10. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

Author

Oliva, Stefania, Genuardi, Elisa, Paris, Laura, D'Agostino, Mattia, Rogers, Jennifer, Rota-Scalabrini, Delia, Jacob, Allison P., Patriarca, Francesca, Luppi, Mario, Bertazzoni, Paola, Velluti, Cristina, Capra, Andrea, Saraci, Elona, Rossi, Marco, Allegra, Alessandro, Mina, Roberto, Gentile, Massimo, Kirsch, Ilan R., Belotti, Angelo, Cavo, Michele, Bruno, Benedetto, Musto, Pellegrino, Boccadoro, Mario, Zamagni, Elena, and Gay, Francesca

Published
2023
Full Text
View/download PDF

11. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Author

Zamagni, Elena, Oliva, Stefania, Gay, Francesca, Capra, Andrea, Rota-Scalabrini, Delia, D'Agostino, Mattia, Belotti, Angelo, Galli, Monica, Racca, Manuela, Zambello, Renato, Gamberi, Barbara, Albano, Domenico, Bertamini, Luca, Versari, Annibale, Grasso, Mariella, Sgherza, Nicola, Priola, Claudia, Fioritoni, Francesca, Patriarca, Francesca, De Cicco, Gabriella, Villanova, Tania, Pascarella, Anna, Zucchetta, Pietro, Tacchetti, Paola, Fanti, Stefano, Mancuso, Katia, Barbato, Simona, Boccadoro, Mario, Musto, Pellegrino, Cavo, Michele, and Nanni, Cristina

Published
2023
Full Text
View/download PDF

12. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

Author

Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, and Sonneveld, Pieter

Published
2023
Full Text
View/download PDF

13. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Author

Paiva, Bruno, Manrique, Irene, Dimopoulos, Meletios A., Gay, Francesca, Min, Chang-Ki, Zweegman, Sonja, Špička, Ivan, Teipel, Raphael, Mateos, María-Victoria, Giuliani, Nicola, Cavo, Michele, Hopkins, Christine Rojas, Fu, Weijun, Suryanarayan, Kaveri, Vorog, Alexander, Li, Cong, Wang, Bingxia, Estevam, Jose, Labotka, Richard, and Dash, Ajeeta B.

Published
2023
Full Text
View/download PDF

14. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Author

Mina, Roberto, Musto, Pellegrino, Rota-Scalabrini, Delia, Paris, Laura, Gamberi, Barbara, Palmas, Angelo, Aquino, Sara, de Fabritiis, Paolo, Giuliani, Nicola, De Rosa, Luca, Gozzetti, Alessandro, Cellini, Claudia, Bertamini, Luca, Capra, Andrea, Oddolo, Daniela, Vincelli, Iolanda Donatella, Ronconi, Sonia, Pavone, Vincenzo, Pescosta, Norbert, Cea, Michele, Fioritoni, Francesca, Ballanti, Stelvio, Grasso, Mariella, Zamagni, Elena, Belotti, Angelo, Boccadoro, Mario, and Gay, Francesca

Published
2023
Full Text
View/download PDF

16. BLOOD PRESSURE VARIABILITY AS PREDICTOR OF CANCER THERAPY-RELATED CARDIOVASCULAR TOXICITY IN PATIENTS WITH MULTIPLE MYELOMA

Author

Fanelli, Elvira, primary, Picca, Giulia, additional, Airale, Lorenzo, additional, Astarita, Anna, additional, Mingrone, Giulia, additional, Catarinella, Cinzia, additional, Votta, Simona, additional, Colomba, Anna, additional, Cesareo, Marco, additional, Leone, Dario, additional, Paladino, Arianna, additional, Rabbia, Franco, additional, Bringhen, Sara, additional, Gay, Francesca, additional, Veglio, Franco, additional, Milan, Alberto, additional, and Vallelonga, Fabrizio, additional

Published
2024
Full Text
View/download PDF

17. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Author

Mateos, Maria-Victoria, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Cavo, Michele, Vij, Ravi, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W. C. J., Ocio, Enrique M., Scheid, Christof, Gay, Francesca, Roeloffzen, Wilfried, Rodriguez-Otero, Paula, Broijl, Annemiek, Potamianou, Anna, Sakabedoyan, Caline, Semerjian, Maria, Keim, Sofia, Strulev, Vadim, Schecter, Jordan M., Vogel, Martin, Wapenaar, Robert, Nesheiwat, Tonia, San-Miguel, Jesus, Sonneveld, Pieter, Einsele, Hermann, and Moreau, Philippe

Published
2022
Full Text
View/download PDF

18. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Author

Dhakal, Binod, Shah, Nina, Kansagra, Ankit, Kumar, Ambuj, Lonial, Sagar, Garfall, Alfred, Cowan, Andrew, Poudyal, Bishesh Sharma, Costello, Caitlin, Gay, Francesca, Cook, Gordon, Quach, Hang, Einsele, Herman, Schriber, Jeff, Hou, Jian, Costa, Luciano, Aljurf, Mahmoud, Chaudhry, Maria, Beksac, Meral, Prince, Miles, Mohty, Mohamad, Janakiram, Murali, Callander, Natalie, Biran, Noa, Malhotra, Pankaj, Otero, Paula Rodriguez, Moreau, Philippe, Abonour, Rafat, Iftikhar, Raheel, Silberman, Rebecca, Mailankody, Sham, Gregory, Tara, Lin, Yi, Carpenter, Paul, Hamadani, Mehdi, Usmani, Saad, and Kumar, Shaji

Published
2022
Full Text
View/download PDF

19. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment.

Author

Colomba, Anna, Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Catarinella, Cinzia, Vallelonga, Fabrizio, Leone, Dario, Cesareo, Marco, Paladino, Arianna, Bringhen, Sara, Gay, Francesca, Pedrizzetti, Gianni, Veglio, Franco, and Milan, Alberto

Subjects
MULTIPLE myeloma, RISK assessment, CROSS-sectional method, VENTRICULAR ejection fraction, RESEARCH funding, VENTRICULAR remodeling, HYPERTENSION, CANCER patient medical care, ONCOLOGY, HEMODYNAMICS, CARDIOVASCULAR diseases risk factors, COMPARATIVE studies, PULSE wave analysis, BIOMARKERS, ECHOCARDIOGRAPHY, DISEASE complications
Abstract

Simple Summary: Multiple myeloma (MM) patients are often affected by cardiovascular (CV) diseases, making baseline CV risk evaluation a fundamental step before starting cardiotoxic drug regimens. Haemodynamic forces (HDFs) analysis is the latest technology for the early identification of myocardial damage. We aimed to identify differences in HDFs analysis in patients with MM, hypertension or both versus normotensive non-oncologic subjects. During echocardiography and pulse wave velocity assessment, hypertensive patients showed decreased ejection fraction, global longitudinal strain and HDFs values compared with normotensive non-oncologic patients, whereas ventricular mass and PWV increased. Multiple myeloma normotensive patients displayed a significant reduction in systolic HDFs and systolic ejection HDFs compared with normotensive non-oncologic patients, but no significant change in terms of standard ventricular markers and PWV was found. Therefore, MM leads to ventricular remodelling regardless of hypertension; HDFs act as early markers of subclinical cardiac damage, and we propose HDFs analysis application in normotensive oncologic patients. Multiple myeloma (MM) affects a population with a high prevalence of cardiovascular (CV) disease. These patients benefit from an accurate CV risk evaluation in order to choose the safest drug regimen. Haemodynamic forces (HDFs) analysis allows for the earlier detection of myocardial damage compared with standard markers; the role played by MM in HDFs alteration, with or without the influence of hypertension, is yet to be studied. Therefore, we aimed to identify differences in HDFs analysis in patients with MM, hypertension or both versus normotensive non-oncologic subjects. A total of 173 patients (MM hypertensive patients, MMHT; MM normotensive patients, MMNT; non-oncologic hypertensive patients, CoHT; and non-oncologic normotensive patients, CoNT) underwent transthoracic echocardiography for HDFs analysis and pulse wave velocity (PWV) assessment. Hypertensive patients (MMHT, CoHT) showed decreased ejection fraction (EF), global longitudinal strain (GLS) and HDFs values compared with CoNT, whereas ventricular mass (LVMi) and PWV increased. MMNT displayed a significant reduction in systolic HDFs (p < 0.006) and systolic ejection HDFs (p < 0.008) compared with CoNT, without significant change in EF, GLS, LVMi or PWV. In conclusion, MM leads to ventricular remodelling regardless of hypertension; HDFs application for MM patients could help detect early myocardial damage, especially in patients receiving cardiotoxic drugs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Author

Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew, and McQuilten, Zoe K.

Subjects
PLASMA cells, MULTIPLE myeloma, STEM cell transplantation, THERAPEUTICS, BONE marrow cells, SURVIVAL analysis (Biometry)
Abstract

Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma & Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia & New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Sonneveld, Pieter, Facon, Thierry, San-Miguel, Jesus, Avet-Loiseau, Hervé, Mohty, Mohamad, Mateos, Maria-Victoria, Moreau, Philippe, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Engelhardt, Monika, Driessen, Christoph, Cook, Gordon, Dimopoulos, Melitios A, Gay, Francesca, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Schreder, Martin, Abildgaard, Niels, Hajek, Roman, Zojer, Niklas, Kastritis, Efstathios, Broijl, Annemiek, Schjesvold, Fredrik, Boccadoro, Mario, and Terpos, Evangelos

Published
2021
Full Text
View/download PDF

22. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Author

Gay, Francesca, Musto, Pellegrino, Rota-Scalabrini, Delia, Bertamini, Luca, Belotti, Angelo, Galli, Monica, Offidani, Massimo, Zamagni, Elena, Ledda, Antonio, Grasso, Mariella, Ballanti, Stelvio, Spadano, Antonio, Cea, Michele, Patriarca, Francesca, D'Agostino, Mattia, Capra, Andrea, Giuliani, Nicola, de Fabritiis, Paolo, Aquino, Sara, Palmas, Angelo, Gamberi, Barbara, Zambello, Renato, Petrucci, Maria Teresa, Corradini, Paolo, Cavo, Michele, and Boccadoro, Mario

Published
2021
Full Text
View/download PDF

23. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Author

Mateos, Maria Victoria, primary, Weisel, Katja, additional, Terpos, Evangelos, additional, Delimpasi, Sossana, additional, Kastritis, Efstathios, additional, Zamagni, Elena, additional, Delforge, Michel, additional, Ocio, Enrique, additional, Katodritou, Eirini, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Leleu, Xavier, additional, Otero, Paula Rodriguez, additional, Schjesvold, Fredik, additional, Cavo, Michele, additional, and Dimopoulos, Meletios A., additional

Published
2024
Full Text
View/download PDF

24. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, primary, Bertuglia, Giuseppe, additional, Rota-Scalabrini, Delia, additional, Belotti, Angelo, additional, Morè, Sonia, additional, Corradini, Paolo, additional, Oliva, Stefania, additional, Ledda, Antonio, additional, Grasso, Mariella, additional, Pavone, Vincenzo, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Ballanti, Stelvio, additional, Velluti, Cristina, additional, Cellini, Claudia, additional, Gozzetti, Alessandro, additional, Palmas, Angelo D., additional, Gamberi, Barbara, additional, Mancuso, Katia, additional, Paris, Laura, additional, Zambello, Renato, additional, Petrucci, Maria Teresa, additional, Bruno, Benedetto, additional, Musto, Pellegrino, additional, and Gay, Francesca, additional

Published
2024
Full Text
View/download PDF

25. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

27. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

29. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Author

Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., and McCarthy, Philip L.

Published
2020
Full Text
View/download PDF

30. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Author

Cavo, Michele, Gay, Francesca, Beksac, Meral, Pantani, Lucia, Petrucci, Maria Teresa, Dimopoulos, Meletios A, Dozza, Luca, van der Holt, Bronno, Zweegman, Sonja, Oliva, Stefania, van der Velden, Vincent H J, Zamagni, Elena, Palumbo, Giuseppe A, Patriarca, Francesca, Montefusco, Vittorio, Galli, Monica, Maisnar, Vladimir, Gamberi, Barbara, Hansson, Markus, Belotti, Angelo, Pour, Ludek, Ypma, Paula, Grasso, Mariella, Croockewit, Alexsandra, Ballanti, Stelvio, Offidani, Massimo, Vincelli, Iolanda D, Zambello, Renato, Liberati, Anna Marina, Andersen, Niels Frost, Broijl, Annemiek, Troia, Rossella, Pascarella, Anna, Benevolo, Giulia, Levin, Mark-David, Bos, Gerard, Ludwig, Heinz, Aquino, Sara, Morelli, Anna Maria, Wu, Ka Lung, Boersma, Rinske, Hajek, Roman, Durian, Marc, von dem Borne, Peter A, Caravita di Toritto, Tommaso, Zander, Thilo, Driessen, Christoph, Specchia, Giorgina, Waage, Anders, Gimsing, Peter, Mellqvist, Ulf-Henrik, van Marwijk Kooy, Marinus, Minnema, Monique, Mandigers, Caroline, Cafro, Anna Maria, Palmas, Angelo, Carvalho, Susanna, Spencer, Andrew, Boccadoro, Mario, and Sonneveld, Pieter

Published
2020
Full Text
View/download PDF

31. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Boccadoro, Mario, Moreau, Philippe, San-Miguel, Jesus, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Facon, Thierry, Driessen, Christoph, Hajek, Roman, Dimopoulos, Melitios A., Gay, Francesca, Avet-Loiseau, Hervé, Terpos, Evangelos, Zojer, Niklas, Mohty, Mohamad, Mateos, Maria-Victoria, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, Engelhardt, Monika, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Abildgaard, Niels, Bringhen, Sara, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

32. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

33. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J., additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodriguez-Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

35. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J, additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodríguez Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

36. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Author

Terpos, Evangelos, Engelhardt, Monika, Cook, Gordon, Gay, Francesca, Mateos, Maria-Victoria, Ntanasis-Stathopoulos, Ioannis, van de Donk, Niels W. C. J., Avet-Loiseau, Hervé, Hajek, Roman, Vangsted, Annette Juul, Ludwig, Heinz, Zweegman, Sonja, Moreau, Philippe, Einsele, Hermann, Boccadoro, Mario, San Miguel, Jesus, Dimopoulos, Meletios A., and Sonneveld, Pieter

Published
2020
Full Text
View/download PDF

38. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Oliva, Stefania, Bruinink, Davine Hofste op, Rihova, Lucie, D’Agostino, Mattia, Pantani, Lucia, Capra, Andrea, van der Holt, Bronno, Troia, Rossella, Petrucci, Maria Teresa, Villanova, Tania, Vsianska, Pavla, Jugooa, Romana, Brandt-Hagens, Claudia, Gilestro, Milena, Offidani, Massimo, Ribolla, Rossella, Galli, Monica, Hajek, Roman, Gay, Francesca, Cavo, Michele, Omedé, Paola, van der Velden, Vincent H. J., Boccadoro, Mario, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

39. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

Author

D’Agostino, Mattia, De Paoli, Lorenzo, Conticello, Concetta, Offidani, Massimo, Ria, Roberto, Petrucci, Maria Teresa, Spada, Stefano, Marcatti, Magda, Catalano, Lucio, Gilestro, Milena, Guglielmelli, Tommasina, Baldini, Luca, Gamberi, Barbara, Rizzi, Rita, De Sabbata, Giovanni, Di Renzo, Nicola, Patriarca, Francesca, Pezzatti, Sara, Siniscalchi, Agostina, Ribolla, Rossella, Palumbo, Antonio, Montefusco, Vittorio, Nagler, Arnon, Boccadoro, Mario, and Gay, Francesca

Published
2018
Full Text
View/download PDF

43. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

Author

Ramasamy, Karthik, primary, Avet-Loiseau, Hervé, additional, Hveding Blimark, Cecilie, additional, Delforge, Michel, additional, Gay, Francesca, additional, Manier, Salomon, additional, Martinez-Lopez, Joaquín, additional, Mateos, Maria Victoria, additional, Mohty, Mohamad, additional, van de Donk, Niels W.C.J., additional, and Weisel, Katja, additional

Published
2023
Full Text
View/download PDF

44. P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA

Author

D’agostino, Mattia, primary, Bruinink, Davine Hofste Op, additional, van Duin, Mark, additional, Rota-Scalabrini, Delia, additional, Bertamini, Luca, additional, Kuiper, Rowan, additional, Belotti, Angelo, additional, Marasco, Vincenzo, additional, Oliva, Stefania, additional, Rivolti, Elena, additional, Rogers, Jennifer, additional, Mina, Roberto, additional, Grasso, Mariella, additional, Ledda, Antonio, additional, Offidani, Massimo, additional, Galli, Monica, additional, Cavo, Michele, additional, Broijl, Annemiek, additional, Musto, Pellegrino, additional, Bruno, Benedetto, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, and Gay, Francesca, additional

Published
2023
Full Text
View/download PDF

45. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

Author

Beksac, Meral, primary, Tuglular, Tulin, additional, Gay, Francesca, additional, Mina, Roberto, additional, Katodritou, Eirini, additional, Unal, Ali, additional, Cavo, Michele, additional, Hayri Ozsan, Guner, additional, van der Velden, Vincent H.J., additional, Beverloo, Berna, additional, Vermeulen, Michael, additional, van Duin, Mark, additional, Cengiz, Guldane, additional, Gokmen Sevindik, Omur, additional, Merante, Serena, additional, Manousou, Kyriaki, additional, Sonneveld, Pieter, additional, and Terpos, Evangelos, additional

Published
2023
Full Text
View/download PDF

46. Lysin (K)-Specific Demethylase 1 Inhibition Enhances Proteasome Inhibitor Response and Overcomes Drug Resistance in Multiple Myeloma

Author

Bandini, Cecilia, primary, Mereu, Elisabetta, additional, Paradzik, Tina, additional, Labrador, Maria, additional, Maccagno, Monica, additional, Cumerlato, Michela, additional, Oreglia, Federico, additional, Prever, Lorenzo, additional, Manicardi, Veronica, additional, Taiana, Elisa, additional, Ronchetti, Domenica, additional, D'Agostino, Mattia, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Merlo, Giorgio, additional, Hirsch, Emilio, additional, Ciarrocchi, Alessia, additional, Inghirami, Giorgio, additional, Neri, Antonino, additional, and Piva, Roberto, additional

Published
2023
Full Text
View/download PDF

49. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Author

Mina, Roberto, Joseph, Nisha S., Gay, Francesca, Kastritis, Efstathios, Petrucci, Maria Teresa, Kaufman, Jonathan L., Montefusco, Vittorio, Gavriatopoulou, Maria, Patriarca, Francesca, Omedé, Paola, Boise, Lawrence H., Roussou, Maria, Giuliani, Nicola, Oliva, Stefania, Offidani, Massimo, Belotti, Angelo, Jaye, David L., De Paoli, Lorenzo, Terpos, Evangelos, Lonial, Sagar, Boccadoro, Mario, Nooka, Ajay K., and Dimopoulos, Meletios A.

Published
2020
Full Text
View/download PDF

50. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Author

Gavriatopoulou, Maria, Musto, Pellegrino, Caers, Jo, Merlini, Giampaolo, Kastritis, Efstathios, van de Donk, Niels, Gay, Francesca, Hegenbart, Ute, Hajek, Roman, Zweegman, Sonja, Bruno, Benedetto, Straka, Christian, Dimopoulos, Meletios A., Einsele, Hermann, Boccadoro, Mario, Sonneveld, Pieter, Engelhardt, Monika, and Terpos, Evangelos

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results